Zitiert in 10+ Publikationen.
Der Kaninchen Polyklonal anti-AGL Antikörper (Klon RB4976) (ABIN1882062) detektiert spezifisch AGL in WB und IF.
Dieser Antikörper reagiert spezifisch mit Proben aus Human.
This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
Immunogen
This AGL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 357-387 amino acids from the Central region of human AGL.
AGL
Reaktivität: Human
WB, IHC, ICC, IP
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
IF: 1:10~50. WB: 1:1000
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Buffer
Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Haltbarkeit
6 months
Irimia, Tagliabracci, Meyer, Segvich, DePaoli-Roach, Roach: "Muscle glycogen remodeling and glycogen phosphate metabolism following exhaustive exercise of wild type and laforin knockout mice." in: The Journal of biological chemistry, (2015) (PubMed).
Guin, Ru, Agarwal, Ritterson Lew, Owens, Comi, Theodorescu: "Loss of glycogen debranching enzyme AGL drives bladder tumor growth via induction of hyaluronic acid synthesis." in: Clinical cancer research : an official journal of the American Association for Cancer Research, (2015) (PubMed).
DePaoli-Roach, Tagliabracci, Segvich, Meyer, Irimia, Roach: "Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin." in: The Journal of biological chemistry, Vol. 285, Issue 33, pp. 25372-81, (2010) (PubMed).
Parker, Kong, Walsh, Salajegheh, Moghadaszadeh, Amato, Nazareno, Lin, Krastins, Sarracino, Beggs, Pinkus, Greenberg: "Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis." in: Muscle & nerve, Vol. 39, Issue 6, pp. 739-53, (2009) (PubMed).
Tagliabracci, Girard, Segvich, Meyer, Turnbull, Zhao, Minassian, Depaoli-Roach, Roach: "Abnormal metabolism of glycogen phosphate as a cause for Lafora disease." in: The Journal of biological chemistry, Vol. 283, Issue 49, pp. 33816-25, (2008) (PubMed).
Cheng, Zhang, Gentry, Worby, Dixon, Saltiel: "A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori's disease." in: Genes & development, Vol. 21, Issue 19, pp. 2399-409, (2007) (PubMed).
Horinishi, Okubo, Tang, Hui, To, Mabuchi, Okada, Mabuchi, Murase: "Mutational and haplotype analysis of AGL in patients with glycogen storage disease type III." in: Journal of human genetics, Vol. 47, Issue 2, pp. 55-9, (2002) (PubMed).
Bao, Dawson, Chen: "Human glycogen debranching enzyme gene (AGL): complete structural organization and characterization of the 5' flanking region." in: Genomics, Vol. 38, Issue 2, pp. 155-65, (1997) (PubMed).
Hansen, Lundin, Markussen, Thorsby: "T cell receptor usage by HLA-DQw8-specific T cell clones." in: International immunology, Vol. 4, Issue 8, pp. 931-4, (1992) (PubMed).
Yang, Ding, Enghild, Bao, Chen: "Molecular cloning and nucleotide sequence of cDNA encoding human muscle glycogen debranching enzyme." in: The Journal of biological chemistry, Vol. 267, Issue 13, pp. 9294-9, (1992) (PubMed).
AGL is a glycogen debrancher enzyme which is involved in glycogen degradation. This enzyme has two independent catalytic activities which occur at different sites on the protein: a 4-alpha-glucotransferase activity and a amylo-1,6-glucosidase activity. Mutations in the AGL gene are associated with glycogen storage disease although a wide range of enzymatic and clinical variability occurs which may be due to tissue-specific alternative splicing.